Patient Characteristics
| Injected activity (MBq) | ||||||||||||
| Patient | Age (y) | Weight (kg) | Height (cm) | TNM | Gleason score | Previous therapy | PSA value (ng/mL) | PSA doubling time (mo) | MSG dose (mg/kg) | Control study | MSG study | Uptake time (min) |
| 1 | 73 | 72.3 | 160 | pT3apN0M0 | 7 (3 + 4) | RP + RT + ADT | 3.3 | 39.2 | 175.66 | 289.9 | 316.1 | 120 |
| 2 | 72 | 86.2 | 170 | cT2acN0M0 | 7 (4 + 3) | RT | 2.13 | 9.9 | 147.33 | 344.8 | 366.8 | 120 |
| 3 | 69 | 85.3 | 173 | cT2ccN0M0 | 8 | RT | 4.67 | 3 | 148.89 | 366.2 | 339 | 120 |
| 4 | 62 | 76.6 | 181 | cT2bcN0M0 | 7 (3 + 4) | RT | 30 | 23.7 | 165.79 | 369.1 | 388.12 | 120 |
| 5 | 75 | 77.6 | 169 | pT3apN0M0 | 7 (4 + 3) | RP | 0.62 | — | 163.66 | 353 | 382.7 | 120 |
| 6 | 71 | 110.2 | 180 | cT2cN0M0 | 7 (3 + 4) | RT + ADT | 6.5 | 5.3 | 115.24 | 410.1 | 410.1 | 120 |
| 7 | 69 | 93 | 183 | pT3bpN0M0 | 7 (4 + 3) | RP + RT | 0.93 | 3.2 | 136.56 | 354.2 | 359.2 | 120 |
| 8 | 76 | 92.3 | 172.5 | pT3apN0M0 | 7 (4 + 3) | RP + RT | 0.92 | 6.7 | 137.59 | 340.9 | 360.8 | 120 |
| 9 | 76 | 92.1 | 180 | pT3apN0M0 | 7 (4 + 3) | RP + RT + ADT | 0.44 | 6.5 | 137.89 | 373 | 348.6 | 120 |
| 10 | 77 | 77.1 | 170 | pT3bpN1M0 | 7 (3 + 4) | RP + RT | 16.7 | 4.2 | 164.72 | 354 | 329.7 | 120 |
PSA = prostate-specific antigen; RP = radical prostatectomy; RT = radiotherapy; ADT = androgen deprivation therapy.